Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Evaluate the Long-Term Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Advance)
Sponsor: Crinetics Pharmaceuticals Inc.
Summary
A phase 2, open label, long-term extension study designed to evaluate the safety and efficacy of paltusotine (formerly CRN00808; an oral selective nonpeptide somatostatin receptor type 2 biased agonist) in subjects with acromegaly.
Official title: An Open Label, Long-term Extension Study to Evaluate the Safety and Efficacy of CRN00808 in Subjects With Acromegaly (ACROBAT Advance)
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
43
Start Date
2020-01-29
Completion Date
2028-03
Last Updated
2026-04-03
Healthy Volunteers
No
Conditions
Interventions
Paltusotine
Paltusotine, once daily by mouth
Locations (22)
Crinetics Study Site
Los Angeles, California, United States
Crinetics Study Site
Chicago, Illinois, United States
Crinetics Study Site
Boston, Massachusetts, United States
Crinetics Study Site
Columbus, Ohio, United States
Crinetics Study Site
Pittsburgh, Pennsylvania, United States
Crinetics Study Site
Pittsburgh, Pennsylvania, United States
Crinetics Study Site
Dallas, Texas, United States
Crinetics Study Site
Curitiba, Paraná, Brazil
Crinetics Study Site
Rio de Janeiro, Brazil
Crinetics Study Site
Rio de Janeiro, Brazil
Crinetics Study Site
São Paulo, Brazil
Crinetics Study Site
München, Germany
Crinetics Study Site
Athens, Greece
Crinetics Study Site 1
Athens, Greece
Crinetics Study Site 2
Athens, Greece
Crinetics Study Site
Thessaloniki, Greece
Crinetics Study Site
Budapest, Hungary
Crinetics Study Site
Budapest, Hungary
Crinetics Study Site
Pécs, Hungary
Crinetics Study Site
Belgrade, Serbia
Crinetics Study Site
Coventry, United Kingdom
Crinetics Study Site
Leeds, United Kingdom